Grafa News and Videos — Page 807

The Ethereum Foundation's Protocol Security team identified and patched a significant security vulnerability in the network's core software after deploying coordinated artificial intelligence agents to analyse the codebase.

Ocugen (NASDAQ:OCGN) signed a binding term sheet with Roots Pharmaceutical and strategic partner Al-Dhow International Holding to negotiate an exclusive license for OCU400, its investigational modifier gene therapy for retinitis pigmentosa, across the Middle East and North Africa region.

Alkermes (NASDAQ:ALKS) reported interim results from its ongoing long-term extension study of alixorexton in adults with narcolepsy type 1 and narcolepsy type 2, showing sustained improvements in wakefulness, sleepiness and patient-reported outcomes after 24 weeks.

Ionis Pharmaceuticals (NASDAQ:IONS) announced that the first participant has been dosed in the Phase 1-2 ASCEND study evaluating ION337, an investigational RNA-targeted medicine for children with Dravet syndrome, a rare neurological disorder.

Bristol Myers Squibb (NYSE:BMY) announced that the U.S. Food and Drug Administration accepted its New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone, known as MeziKd, for patients with relapsed or refractory multiple myeloma.

Q32 Bio (NASDAQ:QTTB) reported positive 36-week topline results from Part B of the Phase 2a SIGNAL-AA trial evaluating bempikibart in 33 patients with severe or very severe alopecia areata.

ANI Pharmaceuticals (NASDAQ:ANIP) reported positive six-month topline results from the Phase 4 SYNCHRONICITY trial evaluating fluocinolone acetonide intravitreal implant 0.18 mg in 108 patients with chronic non-infectious uveitis affecting the posterior segment.

Brightstar Lottery (NYSE:BRSL) announced that its subsidiary Brightstar Global Solutions received a seven-year contract extension to continue as the primary technology supplier for Washington’s Lottery through June 30, 2036.

XRP (CRYPTO:XRP) was trading at US$1.0801, pressing against the upper boundary of a descending channel that has governed its price trajectory for the past 12 months, with the gap between current price and falling resistance now reduced to nearly nothing.

Lazard (NYSE:LAZ) reported preliminary assets under management of approximately $284.7 billion as of June 30, 2026, reflecting market gains, currency movements and the acquisition of a controlling interest in Elaia Partners.